Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the modulation of pergolide, a D1/D2 receptor
agonist, to placebo in non-acute schizophrenic subjects under concomitant therapy with
atypical antipsychotics on specific PFC functions. Further aims are to assess the influence
of pergolide on psychopathology and extrapyramidal symptoms in comparison to placebo.